How does Clesrovimab stop RSV from making my baby sick?
Clesrovimab is a monoclonal antibody—a lab-made protein that acts like a trained guard for your baby's immune system. It binds to the RSV virus's outer coat (called the F protein) and neutralizes it before the virus can infect lung cells, reducing severe disease risk by 80% [1].
The clinical trial data is crystal clear. In healthy infants, Clesrovimab cut RSV hospitalizations from about 3–4% down to 0.5–1% over a 150-day window [1]. In high-risk babies (premature or with heart/lung disease), the protection jumped to 88–92% [3]. That's not a small difference—it's the difference between a mild cold at home and a week in the pediatric ICU on oxygen.
Inside your baby's body, Clesrovimab circulates in the bloodstream and lungs, waiting for RSV particles. When it finds one, it locks onto the F protein like a key in a lock, preventing the virus from fusing with lung cells and spreading infection [3]. Your baby's own immune system then clears the neutralized virus. This happens silently—your baby feels nothing, but the protection is working 24/7.
The real-world trade-off is timing. You need to give Clesrovimab *before* RSV season (October–November in most of North America) because it takes a few days to reach peak protection [1]. If your baby is already coughing and wheezing with RSV, the shot won't reverse the infection—it prevents future infections. That's why pediatricians call it 'prophylaxis' (prevention), not treatment.
Ask your pediatrician at your baby's 2-month checkup: 'Is my baby at high risk for severe RSV?' If yes (premature, heart/lung disease, daycare, or multiple siblings), schedule the Clesrovimab injection before October. If your baby is healthy and born at term, discuss whether the 80% reduction in hospitalization risk is worth the $107 cost or copay.